Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Advanced Micro Devices (AMD) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance

Advanced Micro DevicesTrade
Bio-Rad Laboratories, Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Advanced Micro Devices vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Advanced Micro Devices trades at $473.42 (market cap $766.54B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B). The key difference: Advanced Micro Devices is far larger — about 81.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Advanced Micro Devices nearer its low. Which is the better fit depends on your goals.

AMDBIO
Market Cap
$766.54B$9.39B
Sector
TechnologyHealth
52-Week High
$580.91$354.54
52-Week Low
$151.14$241.71
Enterprise Value
$757.71B$9.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Advanced Micro Devices

AMD trades at $483.36, down 1.21% on the day, near its pivot point of $487 with support at $473 and resistance at $497. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $1.66 versus $1.62 expected, and revenue growth accelerating to $34.64 billion in 2025 from $25.8 billion in 2024. Operating cash flow surged to $7.71 billion in 2025, supporting investments in AI and data center segments. Technical indicators are neutral overall, with RSI levels suggesting balanced momentum.

Outlook remains positive driven by AI demand and market share gains, but high valuation multiples pose risks. Analyst consensus is bullish with a $615.11 price target, though competition and execution challenges warrant caution. The stock offers growth exposure but requires monitoring of competitive dynamics and margin sustainability.

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.

The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Advanced Micro Devices

Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.

Read more on AMD

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO